007460.KS
Aprogen Medicines Inc.
KSC · Industrials · Industrial - Machinery · KR
KRW 2,080.00
+0.97%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 138.9B | 118.0B | 150.1B | 150.6B | 78.3B |
| Cost of Revenue | 110.7B | 84.7B | 115.2B | 114.8B | 72.2B |
| Gross Profit | 28.2B | 33.2B | 34.9B | 35.8B | 6.2B |
| Operating Expenses | |||||
| R&D Expense | 30.9B | 45.8B | 56.8B | 42.8B | 38.6B |
| SG&A Expense | 59.3B | 35.0B | 29.0B | 40.9B | 41.0B |
| General & Admin Expense | 14.7B | 15.6B | 8.8B | 20.8B | 29.1B |
| Selling & Marketing Expense | 17.0B | 19.4B | 20.2B | 20.0B | 11.9B |
| Other Expenses | 45.9B | 48.0B | 35.9B | 41.0B | 41.0B |
| Total Operating Expenses | 127.7B | 128.8B | 121.7B | 124.7B | 120.5B |
| Cost and Expenses | 238.4B | 213.5B | 236.9B | 239.4B | 192.7B |
| Operating Income (EBIT) | (99.5B) | (141.5B) | (86.8B) | (88.9B) | (114.4B) |
| Non-Operating | |||||
| Interest Income | 8.1B | 7.0B | 4.9B | 3.7B | 3.0B |
| Interest Expense | 7.5B | 4.9B | 1.0B | 1.8B | 9.9B |
| Net Interest Income | 522.0M | 2.1B | 3.8B | 1.9B | (6.9B) |
| Other Non-Op Income/Expense | (37.8B) | 4.2B | (11.9B) | (6.4B) | (1.3B) |
| Non-Operating Income (excl Interest) | 44.6B | — | 10.9B | 5.7B | (9.9B) |
| EBT (Pre-Tax Income) | (132.2B) | (137.2B) | (98.7B) | (95.2B) | (115.6B) |
| Income Tax Expense | 3.6B | 511.8M | 1.7B | 2.0B | 473.8M |
| Bottom Line | |||||
| Net Income | (82.8B) | (69.5B) | (58.1B) | (55.6B) | (116.1B) |
| Earnings from Cont. Ops | (135.8B) | (137.8B) | (100.4B) | (97.3B) | (116.1B) |
| Earnings from Discont. Ops | — | — | — | — | 1.2B |
| Bottom Line Net Income | (82.8B) | (69.5B) | (58.1B) | (55.6B) | (98.7B) |
| Per Share | |||||
| Basic EPS | (₩31,115) | (₩52,534) | (₩50,552) | (₩52,961) | (₩389,274) |
| Diluted EPS | (₩30,047) | (₩52,534) | (₩50,552) | (₩52,961) | (₩386,975) |
| Revenue Per Share | ₩6,434 | ₩80,583 | ₩130,660 | ₩143,384 | ₩262,734 |
| Shares | |||||
| Basic Shares Outstanding | 21.6M | 1.5M | 1.1M | 1.1M | 298208 |
| Diluted Shares Outstanding | 21.6M | 1.5M | 1.1M | 1.1M | 299980 |
| Profitability Metrics | |||||
| EBITDA | (120.9B) | (113.9B) | (73.4B) | (65.5B) | (76.1B) |
| D&A | 23.2B | 23.6B | 24.3B | 29.1B | 28.3B |
| EBIT | (144.1B) | (137.5B) | (97.7B) | (94.6B) | (104.5B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026